MEDDEV 2.7.1 Revision 4: Guidelines for Clinical Evaluation

By |2021-10-07T01:19:18+00:00October 7th, 2021|

In accordance with the European directive for medical devices 93/42/EEC, ‘manufacturers must provide proof of and document the performance and safety of medical devices in a "clinical evaluation"’. With the breast implant scandal in mind, in order to (re-)establish confidence in regulatory processes, authorities are demanding greater patient protection. This has led to increased [...]

Systematic Literature Review

By |2021-08-31T02:58:41+00:00August 31st, 2021|

In May 2021, the European Medical Device Directive (93/42/EEC) was replaced with the Medical Device Regulation (MDR, 2017/745). Unlike the MDD, the MDR considers clinical evaluation to take place during the full lifecycle of medical devices, meaning clinical data must be updated continuously. Seeing as clinical data is usually sourced from clinical investigations, post-market [...]

Breaking Down EU MDR Implementation for Class 1 Medical Devices

By |2021-07-10T06:39:53+00:00April 19th, 2021|

Breaking Down EU MDR Implementation for Class 1 Medical Devices Following the one-year delay in the MDR Date of Application, the Class I medical devices, in the lowest risk class, must also conform to the new European Medical Device Regulation (EU MDR) to the end of their required performance lists. Despite any extension period, [...]

Are You Over Committing to Your EU MDR Post Market Surveillance Plan?

By |2021-07-10T17:47:43+00:00March 12th, 2021|

  Overview The EU MDR and IVDR will usher in increased post-market surveillance (PMS) requirements for all MedTech companies. A PMS plan will incorporate a Post-Market Clinical Follow-up (PMCF) plan or justification for why it is unnecessary. Higher-risk devices and IVDs will require a Periodic Safety Update Report (PSUR). While for lower-class devices, a [...]

Classifying Software as Medical Device in EU MDR

By |2021-07-10T17:22:59+00:00March 9th, 2021|

Introduction to Software as a Medical Device in MDR The MDCG’s Guidance document defines the criteria for software qualification falling within the scope of the EU MDR and IVDR. This doc even seeks to elucidate which software will be considered a medical device (qualification) and its subsequent risk classification (classification). Although it is not [...]

How to Hire a Literature Search (or CER) Writer and What to Look For?

By |2021-07-11T17:00:08+00:00January 27th, 2021|

INTRODUCTION A literature search is a deliberate and efficient search from already distributed information to distinguish between a good quality reference on a particular topic. There are different reasons for conducting a literature search, including drawing information for making evidence-based reports, academic assessment, and a step in the research methods. A thorough literature search [...]

UK details a Post-Brexit Medical Device Regime Starting January

By |2021-07-11T17:26:46+00:00December 14th, 2020|

With ongoing negotiations over a trade deal between the UK and the EU and less than 30 days until the end of the Brexit transition period, the UK Government continues to flesh out guidance on regulating medical devices. Given the current circumstances, the Brexit transition period will end without a trade deal in place [...]

Post-Brexit Medical Device Regulatory Compliance – UK MHRA Guidance

By |2021-07-18T18:22:26+00:00November 26th, 2020|

What the Medicines and Healthcare products Regulatory Agency does MHRA is an executive agency in the Department of Health and Social Care. The Medicine and Healthcare products Regulatory Agency regulates medicines and devices for transfusion in the UK. MHRA regulates medicines, medical devices, and blood components. Following the UK Medicines and Healthcare products Regulatory [...]

An Understanding of the Clinical Evaluation Process in China – Comparison with EU MDR

By |2021-07-22T16:49:28+00:00September 17th, 2020|

Medical device regulations in China are often similar to the European Union (EU)’s MDR. With a vital prerequisite of Clinical Evaluation Reports (CERs), as required by China’s National Medical Products Administration NMPA (formerly CFDA). Although both the forgoing regulatory frameworks permit equivalent devices as a basis for clinical data for a new device, the [...]

Go to Top